Riyadh – Mubasher: Qomel Company announced the signing of a significant framework agreement with the National Unified Procurement Company for Medicines, Medical Devices, and Medical Supplies, commonly known as NUPCO.
The contract is valued at approximately SAR 21.55 million and involves the supply of pharmaceutical products on an as-needed basis, according to a bourse disclosure.
This strategic agreement is expected to bolster Qomel Company’s revenue streams over a multi-year period.
Meanwhile, the financial impact projected to begin appearing in the company’s fiscal reports starting from the second half (H2) of 2026.
The agreement was formally executed on 6 July 2026. Under the terms of the framework agreement, Qomel Company will be responsible for the supply of various medicines and medical products as requested by NUPCO, which serves as the central procurement arm for the Saudi Arabian healthcare sector.
The contract is structured as a service and supply agreement with a total duration of 1,055 days. This extended timeframe provides Qomel Company with a long-term operational window to fulfill procurement orders, aligning with the Kingdom’s broader objectives to ensure a steady and reliable supply of essential medical commodities to public health institutions.
The nature of the "on-demand" supply contract allows for flexibility in delivery schedules based on the specific requirements of the national healthcare infrastructure managed by NUPCO.
Regarding the financial implications of this deal, Qomel stated that the positive impact is anticipated to be reflected. This timeline corresponds with the commencement of the supply operations and the subsequent recognition of revenue as orders are fulfilled under the framework’s terms.
Investors and stakeholders are advised that the realization of these financial gains will be spread across the duration of the 1,055-day contract period.
In compliance with transparency and governance standards required by the Capital Market Authority (CMA), Qomel Company confirmed that there are no related parties involved in this transaction. This indicates that the contract was awarded through standard procurement procedures without any conflict of interest involving the company’s board of directors or major shareholders.
It is worth noting that in June 2026, the listed company penned contracts totaling SAR 214.26 million with NUPCO which plays a pivotal role in the Saudi healthcare landscape by centralizing the purchasing of medical supplies for government agencies.
By securing this contract, Qomel reinforces its position as a key supplier within the local pharmaceutical and medical distribution market, contributing to the efficiency of the national health supply chain.
